Research programme: Alzheimer's disease therapies - BioFocus/Senexis
Alternative Names: β-sheet breakersLatest Information Update: 16 Jul 2016
At a glance
- Originator Galapagos NV; Senexis
- Class Small molecules
- Mechanism of Action Amyloid inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in United Kingdom (PO)
- 12 Dec 2005 Senexis and Galapagos have expanded their collaboration to include optimisation of novel inhibitors of amyloid-induced toxicity and neuroinflammation in the UK for Alzheimer's disease
- 04 Nov 2005 BioFocus has been acquired and merged into Galapagos NV